PAM
CGON icon

Pamalican Asset Management’s CG Oncology CGON Stock Holding History

Pamalican Asset Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-181,582
Closed -$5.21M – 13
2024
Q4 		$5.21M Buy
+181,582
New +$6.21M 2.3% 15

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return

Pamalican Asset Management's CGON Position: Q1 2025 in Review

Pamalican Asset Management sold out of CG Oncology (CGON) in Q1 2025, closing a stake of 181,582 shares — an estimated $5.21M sold.

Pamalican Asset Management first reported a position in CGON in Q4 2024 and held it in 1 quarter. The position peaked at $5.21M in Q4 2024. 142 funds tracked by Wall St. Rank hold CGON as of Q1 2025.

  • Pamalican Asset Management reported no remaining CG Oncology position as of Q1 2025 after selling out during the quarter.
  • Pamalican Asset Management sold 181,582 CG Oncology shares in Q1 2025, an estimated $5.21M.
  • Pamalican Asset Management first reported a position in CG Oncology in Q4 2024 and held it in 1 quarter.
  • Pamalican Asset Management's CG Oncology position peaked at $5.21M in Q4 2024.
  • 142 funds tracked by Wall St. Rank held CG Oncology as of Q1 2025.

Based on Pamalican Asset Management's 13F filing for Q1 2025, filed 9 May 2025.